Physician profile
Luke Barre
NPI 1689938037
$4,687.24
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $575 · 2021: $960 · 2022: $886 · 2023: $675 · 2024: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.29 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.52 | 2019-2024 | Rinvoq, Skyrizi |
| Amgen INC. | $1,054.31 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $531.80 | 2019-2024 | Tremfya |
| Glaxosmithkline, LLC. | $287.94 | 2019-2024 | Benlysta |
| Lilly USA, LLC | $263.73 | 2019-2023 | Taltz |
| Hikma Pharmaceuticals USA | $207.74 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $191.14 | 2019-2024 | Orencia |
| Genentech USA, INC. | $134.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $126.01 | 2022-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $99.73 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $98.15 | 2019-2022 | |
| Horizon Therapeutics Plc | $84.28 | 2021 | |
| Genzyme Corporation | $72.53 | 2024 | |
| Pfizer INC. | $53.54 | 2019-2022 | |
| Ucb, INC. | $38.76 | 2023-2024 | Cimzia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.04 | 2020 | |
| Acorda Therapeutics, INC | $13.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Barre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.